Journal of Infection and Public Health (Feb 2020)
Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies
- P. Cahn,
- J. Sierra Madero,
- J. Arribas,
- A. Antinori,
- R. Ortiz,
- A. Clarke,
- C. Hung,
- J. Rockstroh,
- P. Girard,
- J. Sievers,
- C. Man,
- R. Urbaityte,
- M. Underwood,
- A. Tenorio,
- K. Pappa,
- B. Wynne,
- M. Gartland,
- M. Aboud,
- J. van Wyk,
- K. Smith,
- Y. El-Bahy
Affiliations
- P. Cahn
- Fundación Huesped
- J. Sierra Madero
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- J. Arribas
- Hospital La Paz
- A. Antinori
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
- R. Ortiz
- Bliss Healthcare Services
- A. Clarke
- Royal Sussex County Hospital and Brighton & Sussex Medical School
- C. Hung
- National Taiwan University Hospital
- J. Rockstroh
- Rheinische Friedrich-Wilhelms Universität
- P. Girard
- Hôpital Saint Antoine
- J. Sievers
- ViiV Healthcare
- C. Man
- ViiV Healthcare
- R. Urbaityte
- GlaxoSmithKline
- M. Underwood
- ViiV Healthcare
- A. Tenorio
- ViiV Healthcare
- K. Pappa
- ViiV Healthcare
- B. Wynne
- ViiV Healthcare
- M. Gartland
- ViiV Healthcare
- M. Aboud
- ViiV Healthcare
- J. van Wyk
- ViiV Healthcare
- K. Smith
- ViiV Healthcare
- Y. El-Bahy
- GlaxoSmithKline; Corresponding author.
- Journal volume & issue
-
Vol. 13,
no. 2
pp. 349 – 350
